Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1
Amy E. Armstrong, Steven D. Rhodes, Abbi Smith, Shi Chen, Waylan Bessler, Michael J. Ferguson, Li Jiang, Xiaohong Li, Jin Yuan, Xianlin Yang, Feng Chun Yang, Kent A. Robertson, David A. Ingram, Jaishri O. Blakeley, D. Wade Clapp
Dive into the research topics of 'Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1'. Together they form a unique fingerprint.